These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27774364)

  • 1. Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism.
    Wang B; Walsh SJ; Saif MW
    Cureus; 2016 Sep; 8(9):e798. PubMed ID: 27774364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes.
    Saif MW; Smith M; Maloney A
    Cureus; 2016 Sep; 8(9):e783. PubMed ID: 27752409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.
    Saif MWM; Hamal R; Siddiqui N; Maloney A; Smith M
    Therap Adv Gastroenterol; 2021; 14():17562848211024464. PubMed ID: 34276810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of
    Abbasian MH; Ansarinejad N; Abbasi B; Iravani M; Ramim T; Hamedi F; Ardekani AM
    Avicenna J Med Biotechnol; 2020; 12(3):157-164. PubMed ID: 32695278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
    Saif MW
    Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
    Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
    Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate Synthase (TYMS) and Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphisms Associated With Severe Capecitabine Toxicity: The First Case From Saudi Arabia.
    Bukhari N; Al-Mohanna H; Almsned F
    Cureus; 2023 Nov; 15(11):e49215. PubMed ID: 38143640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-dependent association of
    Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
    Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report.
    Baskin Y; Amirfallah A; Unal OU; Calibasi G; Oztop I
    Am J Ther; 2015; 22(2):e36-9. PubMed ID: 24434920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
    Balboa-Beltrán E; Duran G; Lamas MJ; Carracedo A; Barros F
    Mayo Clin Proc; 2015 Sep; 90(9):1298-303. PubMed ID: 26210704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
    Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
    Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Case of Foot Drop Associated with Capecitabine in a Patient with Thymidylate Synthase Polymorphism.
    Wilks AB; Saif MW
    Cureus; 2017 Jan; 9(1):e995. PubMed ID: 28280649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.